Hansa Biopharma AB OMXSTO:HNSA:
HANSA BIOPHARMA ANNOUNCES CLOSING OF €115 MILLION LICENSING TRANSACTION WITH SERB PHARMACEUTICALS FOR IDEFIRIX IN EUROPE AND MENA
DEAL INCLUDES €110 MLN UPFRONT AND €5 MLN ON EMA FILING ACCEPTANCE
SERB TO ASSUME LONG-TERM PAES FOLLOW-UP AND PAEDIATRIC STUDY RESPONSIBILITY